23 November 2020: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, announces its intention to raise gross proceeds of up to £13.9 million by means of a placing to institutional and other investors (the “Placing“) and a direct subscription with the Company to raise gross proceeds of up to £1.1 million (the “Subscription“), in each case at a price of 70 pence per share (“Issue Price“). The net proceeds of the Placing and Subscription will allow the Group, inter alia, to deliver extended clinical data from its ongoing retinitis pigmentosa (RP) Phase 2a study and to deliver proof-of-concept pre-clinical data from ongoing exosome collaborations which could enable potential out-licensing deals, as detailed below more fully.